NTLA - CIK 0001652130
Intellia Therapeutics, Inc. (NTLA) reported net income of -$412.69M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$412.69M | +20.5% |
| FY 2024 | -$519.02M | -7.9% |
| FY 2023 | -$481.19M | -1.5% |
| FY 2022 | -$474.19M | -77.0% |
| FY 2021 | -$267.89M | -99.6% |
| FY 2020 | -$134.23M | +71.7% |
| FY 2019 | -$474.19M | -455.6% |
| FY 2018 | -$85.34M | -26.4% |
| FY 2017 |
Intellia Therapeutics, Inc. (NTLA) reported net income of -$412.69M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, Intellia Therapeutics, Inc.'s net income declined from -$12.40M to -$412.69M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$67.54M |
| -113.5% |
| FY 2016 | -$31.63M | -155.2% |
| FY 2015 | -$12.40M | - |